MDxHealth SA

MDxHealth SA (MDXH) priced its initial public offering on Nov 5, 2021 at $12.00 per ADS, raising $45M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $187.2M. Piper Sandler was lead-left underwriter, joined by BTIG, Oppenheimer and KBC. Baker McKenzie and K&L Gates advised the company and DLA Piper advised the underwriters.

MDxHealth SA is a commercial-stage precision diagnostics company offering non-invasive urologic solutions. Its prostate cancer genomic tests, SelectMDx and ConfirmMDx, help physicians identify clinically significant prostate cancer while minimizing invasive procedures.

Status

IPO

Ticker

MDXH

Exchange

Nasdaq Capital Market

Priced

Nov 5, 2021

IPO price

$12.00 per ADS

Raised

$45M

Market cap at IPO price

$187.2M

First filed

Oct 13, 2021

Underwriters

Piper Sandler, BTIG, Oppenheimer and KBC

Company counsel

Baker McKenzie and K&L Gates

Underwriters' counsel

DLA Piper

Sector

Healthcare

Country / state

Belgium

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.